drugset / Trial / NCT02446301

A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection in Healthy Volunteers

NCT02446301

Phase 1 Completed 12 enrolled Lumosa Therapeutics Co., Ltd.
Non-randomizedCrossoverOpen-labelTreatment

Summary

This study is to evaluate the relative bioavailability of nalbuphine after single IM injection of Sebacoyl Dinalbuphine Ester (SDE) injection and Bain®, Nalbuphine HCl IM injection in healthy volunteers.

Timeline

Start
2015-01
Primary completion
2015-04
Completion
2015-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Dinalbuphine sebacate Small molecule 150 mg Intramuscular
Subject Nalbuphine Small molecule 20 mg Intramuscular